-
Product Insights
Hypertrophic Cardiomyopathy - Global Clinical Trials Review, 2026
GlobalData's clinical trial report, “Hypertrophic Cardiomyopathy - Global Clinical Trials Review, 2026" provides an overview of Hypertrophic Cardiomyopathy Clinical trials scenario. This report provides top line data relating to the clinical trials on Hypertrophic Cardiomyopathy. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Product Insights
Neurogenic Orthostatic Hypotension (nOH): Global Clinical Trials Review, 2025
GlobalData's clinical trial report, “Neurogenic Orthostatic Hypotension (nOH) - Global Clinical Trials Review, 2025" provides an overview of Neurogenic Orthostatic Hypotension (nOH) Clinical trials scenario. This report provides top line data relating to the clinical trials on Neurogenic Orthostatic Hypotension (nOH). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and...
-
Product Insights
Thrombotic Microangiopathy: Global Clinical Trials Review, 2025
GlobalData's clinical trial report, “Thrombotic Microangiopathy - Global Clinical Trials Review, 2025" provides an overview of Thrombotic Microangiopathy Clinical trials scenario. This report provides top line data relating to the clinical trials on Thrombotic Microangiopathy. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Sector Analysis
Atrial Fibrillation Major Markets Drug Forecast and Market Analysis
The table below presents the key metrics for atrial fibrillation (AF) in the eight major pharmaceutical markets (8MM) covered in this report—the US, 5EU (France, Germany, Italy, Spain, and the UK), Japan, and Canada—during the forecast period from 2022–32. In 2022, GlobalData estimated that the global AF market reached $14.5 billion across the 8MM. The US makes up the majority of total global sales, contributing $10.7 billion (74%) due to the large prevalent AF population in the US, early adoption...
-
Product Insights
Acute Decompensated Heart Failure Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
GlobalData's clinical trial report, “Acute Decompensated Heart Failure - Global Clinical Trials Review, 2025" provides an overview of Acute Decompensated Heart Failure Clinical trials scenario. This report provides top line data relating to the clinical trials on Acute Decompensated Heart Failure. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and...
-
Sector Analysis
Dilated Cardiomyopathy (DCM) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
This reports provides a data-driven overview of the current and future competitive landscape in Dilated Cardiomyopathy Therapeutics. - In 2024, more than three million diagnosed prevalent cases of DCM are anticipated in the 16 countries covered in GlobalData’s epidemiology forecast. - The treatment of DCM is primarily focused on symptom management using beta-blockers, ACE inhibitors, ARBs, MRAs, and SGLT2 inhibitors. - Currently, 34 molecules are being developed for DCM across various stages of the pipeline. - Over the past 10...
-
Sector Analysis
Hypertrophic Cardiomyopathy (HCM) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
This reports provides a data-driven overview of the current and future competitive landscape in Hypertrophic Cardiomyopathy Therapeutics. - In 2024, more than two million diagnosed prevalent cases of HCM are anticipated in the 16 countries covered in GlobalData’s epidemiology forecast. - HCM management has traditionally relied on generic beta-blockers and calcium channel blockers to alleviate symptoms. - A total of 34 molecules are in development for HCM, including two drugs in the pre-registration stage, two drugs in Phase III, and...
-
Product Insights
Stroke Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
GlobalData's clinical trial report, “Stroke - Global Clinical Trials Review, 2025" provides an overview of Stroke Clinical trials scenario. This report provides top line data relating to the clinical trials on Stroke. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress...
-
Sector Analysis
Heart Failure in 68 Markets - Disease Overview, Product Profiles, Patient Flow, Competitive Assessment and Sales Forecast to 2032
Heart Failure Market Report Overview The heart failure market size across the 68M was $21.6 billion in 2022. The “Heart Failure in 68 Markets” research report covers the 68 geographical markets and provides an Excel-based forecast model for the market through 2033. Heart Failure Market Outlook, 2022-2033 ($ Billion) Buy the Full Report for More Insights on the Heart Failure Market Report Forecast Download a Free Report Sample The Heart Failure market report contains patient-based forecast sales data for the...
-
Sector Analysis
Acute Coronary Syndrome Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Acute Coronary Syndrome Marketed and Pipeline Drugs Market Overview The term acute coronary syndrome (ACS) applies to a spectrum of acute cardiovascular (CV) disease states that are precipitated by coronary artery occlusion (stenosis) resulting in ischemia (a reduction or loss of blood flow to tissue) and the necrosis (death) of myocardial tissue. In the most modern use of the term, ACS strictly refers to a range of ischemic CV events that include UA, myocardial infarction (MI), and death due to...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.